Company intelligence / Profile preview

Vertanical

Gräfelfing, Bavaria, Germany

Ownership: Private
Employees: ~53
Development stage: Preclinical

Overview

Vertanical has completed two large Phase 3 trials of its lead product, VER-01, a non-opioid, full-spectrum cannabis-based medicine for chronic low back pain. The trials demonstrated efficacy and safety compared to both placebo and opioids. Regulatory submissions are underway in Europe and the UK as of mid/late 2024, with US registration trials planned for 2025. The company positions VER-01 as a potential opioid alternative without dependency or abuse potential.[1][2][3][4][5]

Therapeutic areas: NeurologyRheumatology
Modalities: Full-spectrum cannabis extract (plant-derived cannabinoids)[5]
Industry: Biotech

Drug pipeline

2 assets

VER-01

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vertanical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vertanical.

Explore the full profile